Cumulus Neuroscience receives £1.8m Biomedical Catalyst grant to expand CNS biomarker platform

First published: 5th April 2021

Cumulus Neuroscience is pleased to announce it has received a Biomedical Catalyst Grant award of £1.8m to help expand its next-generation integrated physiological and digital biomarker platform.

The Biomedical Catalyst (BMC) is a unique partnership between the Medical Research Council (MRC) and Innovate UK, providing support to the most innovative life science opportunities regardless of scientific approach. The BMC aims to de-risk innovative science and commercialise ideas arising out of academia and industry, helping UK SMEs to develop into competitive and sustainable organisations.

Cumulus’ innovative platform provides the critical data and insights needed for faster, more robust and cost-effective execution and evaluation of clinical trials in neuroscience. This addresses the significant unmet need to accelerate the delivery of more effective CNS drugs to patients.

In the project funded by this grant, Cumulus will build upon the platform to incorporate integrated, synchronous assessment of a broader range of domains that are particularly relevant in dementia. Specifically, the Company will test and validate integration of best-in-class tools measuring brain activity, cognition, mood, speech, and sleep staging.

The project will demonstrate the Company's ability to track longitudinal progression across multiple domains outside of the clinic, enabling higher precision and greater understanding of the different underlying mechanisms of disease in a real world setting to streamline clinical trial execution.

Cumulus Neuroscience CEO Ronan Cunningham commented: “We are thrilled that the Biomedical Catalyst has recognised the exciting potential of Cumulus’ platform with this grant award. Providing a single platform to unify multiple measurements for clinical trials will significantly reduce patient burden, minimise variability across studies and dramatically reduce timelines and cost for drug developers – ultimately leading to a better understanding of disease and faster routes to market for promising treatments in the CNS space.”